Submitted:
31 December 2025
Posted:
02 January 2026
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Psychological, Medical, and Ecological Perspectives Influencing the Behavior of the Patient Diagnosed with HIV
3. HIV Management
4. Conclusions
References
- Lifson, AR; Belloso, WH; Carey, C; et al. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials. 2008, 9, 177–185. [Google Scholar] [CrossRef]
- Deeks, SG; Phillips, AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009, 338, a3172. [Google Scholar] [CrossRef]
- Baker, J; Ayenew, W; Quick, H; et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infectious Dis. 2010, 201, 285–292. [Google Scholar] [CrossRef]
- Funderburg, NT; Mayne, E; Sieg, SF; et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010, 115, 161–167. [Google Scholar] [CrossRef]
- Neuhaus, J; Jacobs, DR, Jr.; Baker, JV; et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010, 201, 1788–1795. [Google Scholar] [CrossRef] [PubMed]
- Jong, E; Louw, S; Meijers, JC; et al. The hemostatic balance in HIV-infected patients with and without anti-retroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS. 2009, 23, 1001–1007. [Google Scholar] [CrossRef]
- Pontrelli, G; Martino, AM; Tchidjou, HK; et al. HIV is associated with thrombophilia and high D-dimer in children and adolescents. AIDS. 2010, 24, 1145–1151. [Google Scholar] [CrossRef] [PubMed]
- Paydas, S.; Ergin, M.; Seydaoglu, G.; Erdogan, S.; Yavuz, S. Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large b cell lymphoma and review of the literature. Leuk. Res. 2009, 33, 1627–1635. [Google Scholar] [CrossRef]
- Bates, D.O. An unexpected tail of vegf and plgf in pre-eclampsia. Biochem. Soc. Trans. 2011, 1576–1582. [Google Scholar] [CrossRef]
- Fagiani, E.; Christofori, G. Angiopoietins in angiogenesis. Cancer Lett. 2013, 328, 18–26. [Google Scholar] [CrossRef]
- Findley, C.M.; Mitchell, R.G.; Duscha, B.D.; Annex, B.H.; Kontos, C.D. Plasma levels of soluble tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J. Am. Coll. Cardiol. 2008, 52, 387–393. [Google Scholar] [CrossRef] [PubMed]
- Engelman, JA; Zejnullahu, K; Mitsudomi, T; Song, Y; Hyland, C; Park, JO.; et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007, 316, 1039–1043. [Google Scholar] [CrossRef] [PubMed]
- Nahta, R; Yuan, LXH; Zhang, B; Kobayashi, R; Esteva, FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65, 11118–111128. [Google Scholar] [CrossRef]
- Muñoz, N; Bosch, FX; de Sanjosé, S; Herrero, R; Castellsagué, X; et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348, 518–527. [Google Scholar] [CrossRef]
- Mork, J; Lie, AK; Glattre, E; Hallmans, G; Jellum, E; et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001, 344, 1125–1131. [Google Scholar] [CrossRef]
- Ray, P., Liu, XH., Xu, L. et al. Basic fibroblast growth factor in HIV-associated hemolytic uremic syndrome. Pediatr Nephrol 13, 586–593 (1999). [CrossRef]
- Bhattacharya, G. Social capital and HIV risks among acculturating Asian Indian men in New York City. AIDS Educ Prev 2005, 17, 555–567. [Google Scholar] [CrossRef] [PubMed]
- Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2021 Dec 06;73(11):e3572-e3605. [CrossRef]
- Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, Thomas DL., Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002 Dec 14;360(9349):1921-6. [CrossRef]
- Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE, Smith RD, Slack M, Delpech VC. Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS. 2012 Jan 02;26(1):87-94. [CrossRef]
- van Heuvel Y, Schatz S, Rosengarten JF, Stitz J. Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine. Toxins (Basel). 2022 Feb 14;14(2).
- Meissner ME, Talledge N, Mansky LM. Molecular Biology and Diversification of Human Retroviruses. Front Virol. 2022;2.
- Centers for Disease Control and Prevention (CDC). Revised surveillance case definition for HIV infection--United States, 2014. MMWR Recomm Rep. 2014 Apr 11;63(RR-03):1-10.
- Moss Joseph Anthony, HIV/AIDS Review, Radiol Technol., . 2013 Jan-Feb;84(3):247-67; quiz p.268-70.
- Landovitz J. Raphael, Scott Hyman Scott , Deeks G. Steven, Prevention, treatment and cure of HIV infection, Nat Rev Microbiol., . 2023 Oct;21(10):657-670.
- Deeks G. Steven, Overbaugh Julie, Phillips Andrew, Buchbinder Susan, HIV infection, Nat Rev Dis Primers . 2015 Oct 1:1:15035.
- UN Joint Programme on HIV/AIDS (UNAIDS). AIDS, crisis and the power to transform: UNAIDS Global AIDS Update 2025 2025, 1–116.
- Goosby, E; Dybul, M; Fauci, AS; Fu, J; Walsh, T; Needle, R; et al. The United States President’s Emergency Plan for AIDS Relief: a story of partnerships and smart investments to turn the tide of the global AIDS pandemic. J Acquir Immune Defic Syndr. 2012, 60 Suppl 3, S51–6. [Google Scholar] [CrossRef] [PubMed]
- Fauci AS, Folkers GK, Lane H. Human immunodeficiency virus disease: AIDS and related disorders. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J et al., editors. Harrison’s principles of internal medicine. 22nd ed. McGraw Hill; 2026.
- Bekker, L-G; Das, M; Abdool Karim, Q; Ahmed, K; Batting, J; Brumskine, W; et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024, 391(13), 1179–92. [Google Scholar] [CrossRef]


Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
